Date:	June 24, 2021	
Your Name:	Yajun Qi	
Manuscript Title:	_MD2 blockage prevent	s the migration and invasion of hepatocellular carcinoma cells via inhibition of
the EGFR signalin	g pathway	
Manuscript numl	ber (if known):JGO-2	1-362

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of t	he work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851)	
	medical writing, article processing charges, etc.)  No time limit for this item.	Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003)	
		Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037)	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	••	
11	Stock or stock options	None	
10		•	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Dr. Qi reported that this manuscript was funded by the National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851), the Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003), and the Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037).

Please place an "X" next to the following statement to indicate your agreement:

Date:	June 24, 2021	
Your Name:	Qilu Fang	
<b>Manuscript Title:</b>	_MD2 blockage prevents	the migration and invasion of hepatocellular carcinoma cells via inhibition of
the EGFR signalin	g pathway	
Manuscript numb	oer (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of t	he work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851) Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003) Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037)	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Dr. Fang reported that this manuscript was funded by the National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851), the Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003), and the Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037).

Please place an "X" next to the following statement to indicate your agreement:

Date:	June 24, 2021	
Your Name:	Qinglin Li	
Manuscript Title:	_MD2 blockage prever	nts the migration and invasion of hepatocellular carcinoma cells via inhibition of
the EGFR signalin	ng pathway	
Manuscript num	ber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning of t	he work
	1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851) Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003) Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037)	
I			Time frame: past 36 months	
	2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
	3	Royalties or licenses	None	
r	4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Dr. Li reported that this manuscript was funded by the National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851), the Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003), and the Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037).

Please place an "X" next to the following statement to indicate your agreement:

Date:	June 24, 2021	
Your Name:	Haiying Ding	
<b>Manuscript Title</b>	:_MD2 blockage prevents	the migration and invasion of hepatocellular carcinoma cells via inhibition of
the EGFR signali	ng pathway	
Manuscript num	ber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of t	he work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851)  Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003)  Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 20107D034, and 2010KY037)	
		2019ZD024, and 2019KY037)  Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Dr. Ding reported that this manuscript was funded by the National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851), the Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003), and the Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037).

Please place an "X" next to the following statement to indicate your agreement:

Date:	_June 24, 2021	
Your Name:	Qi Shu	
Manuscript Title:_[	blockage prevents the migration and invasion of hepatocellular carcinoma cells via inhibition	on of
the EGFR signaling	nway	
Manuscript numbe	known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of t	he work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851)  Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003)  Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037)	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Compared for attending	Name	
/	Support for attending meetings and/or travel	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
40			
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. Shu reported that this manuscript was funded by the National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851), the Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003), and the Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037).

Please place an "X" next to the following statement to indicate your agreement:

Date:	June 24, 2021	
Your Name:	Yan Hu	
Manuscript Title:	_MD2 blockage prevents	the migration and invasion of hepatocellular carcinoma cells via inhibition of
the EGFR signalin	g pathway	
Manuscript numl	ber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of t	he work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851)  Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003)  Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037)	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
_			
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	News	
13	financial interests	None	
	ווומוונומו ווונכופטנט		

Dr. Hu reported that this manuscript was funded by the National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851), the Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003), and the Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037).

Please place an "X" next to the following statement to indicate your agreement:

Date:	June 24, 2021	
Your Name:	Wenxiu Xin	
Manuscript Title:	_MD2 blockage prevent	s the migration and invasion of hepatocellular carcinoma cells via inhibition of
the EGFR signalir	ng pathway	
Manuscript num	ber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of t	he work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851) Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003) Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037)	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	testimony		
-	Comment for out on the control of	None	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	periang		
9	Double in a tien and a Date	News	
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests	None	
	inialiciai liiterests		

Dr. Xin reported that this manuscript was funded by the National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851), the Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003), and the Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037).

Please place an "X" next to the following statement to indicate your agreement:

Date:	June 24, 2021	
Your Name:	Luo Fang	
Manuscript Title:	_MD2 blockage prevents t	he migration and invasion of hepatocellular carcinoma cells via inhibition of
the EGFR signalin	g pathway	
Manuscript numl	ber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning of t	he work
	1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851) Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003) Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037)	
I			Time frame: past 36 months	
	2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
	3	Royalties or licenses	None	
r	4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Dr. Fang reported that this manuscript was funded by the National Natural Science Foundation of China (Grant No. 81903898, 81773819, 81973396, and 82003851), the Zhejiang Provincial Natural Science Foundation of China (Grant No. YY19H310003), and the Medical Science and Technology Program of Zhejiang province (Grant No. 2013KYA027, 2017190933, 2016KYB038, 2019ZD024, and 2019KY037).

Please place an "X" next to the following statement to indicate your agreement: